By the Top Tier Newswire AI Desk · November 17, 2026 at 10:23 AM ET · reviewed against 13 wire stories
OMEROS CORP (OMER) is down -20.56% in the latest session. Our newswire has captured 13 stories on OMER across 7 sources in the last 36 hours, with AI sentiment reading mixed (avg 53/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Omeros Corp (OMER) shares fell 20.56% to $13.25, driven by a negative opinion from EU regulators for its drug narsoplimab despite strong sales growth for its lead product. The stock printed two fresh 52-week lows on November 17, 2026, as the market weighed the regulatory setback against the company’s improving cash flow metrics.
What Happened
Omeros reported third-quarter 2026 results showing that YARTEMLEA gross sales rose 30% to $41.8 million. The company also reported $13.3 million in operating cash flow, marking a positive turn for the business. However, the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion for narsoplimab. Omeros expects fourth-quarter 2026 discontinued operations income of $5 million to $6 million while it scales YARTEMLEA education and outpatient use.
What The Data Shows
The stock opened at $15.35, an 8.0% gap down from the prior close of $16.68. It hit a session high of $15.46 at 7:15 AM ET and a session low of $12.70 at 9:30 AM ET before settling near $13.33. Volume so far stands at 1.0 million shares, which is 0.7 times the three-month daily average. The company has a market cap of $1.3 billion, a P/E ratio of 11.4, and a net margin of 324.9%. Its beta is 2.99, and the 52-week range is $6.59 to $21.24. Over the last 8 sessions, the stock moved down 2.3% from $17.07 to $16.68. In the last 90 days, there were 0 insider buys and 5 sells totaling $2.1 million, with the most recent filing on September 24, 2026.
What To Watch
Investors will monitor the company’s ability to offset the EU regulatory setback with continued YARTEMLEA growth. The upcoming coverage and any further regulatory updates will be key factors in determining the stock’s near-term direction.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Nov 16, 2026 / 09:30PM GMTOperator Good afternoon and welcome to today's earnings call for Omeros Corporation. (Operator Instructions) Please be advised that th
3d agoStocktwits NewsBULLISH 58Earnings
Dow, S&P 500, Nasdaq Futures Mixed Ahead Of Much-Anticipated Nvidia Earnings, Anthropic IPO: SLS, BABA, JPM, OMER In Focus
Anthropic’s public listing, expected on Wednesday, could top $1.4 trillion in valuation, stoking a key test for Wall Street's AI appetite.
Omeros Corporation (OMER) Q3 2026 Earnings Call November 16, 2026 4:30 PM ESTCompany ParticipantsGregory Demopulos - Co-Founder, Chairman, CEO &...
3d agoInvesting.com MarketsBEARISH 38General
Why is Omeros stock sliding today?
Why is Omeros stock sliding today?
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →